Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ponesimod - Actelion Pharmaceuticals

Drug Profile

Ponesimod - Actelion Pharmaceuticals

Alternative Names: ACT-128800; Compound 8bo - Actelion; R-3477; RG 3477

Latest Information Update: 13 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Actelion Pharmaceuticals
  • Class Antipsoriatics; Chlorobenzenes; Imines; Phenyl ethers; Small molecules; Thiazolidines
  • Mechanism of Action Immunomodulators; Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple sclerosis
  • Phase II Graft-versus-host disease
  • No development reported Immunological disorders; Plaque psoriasis

Most Recent Events

  • 11 Sep 2019 Efficacy and adverse events data from a phase III OPTIMUM trial in Multiple sclerosis presented at the (35th Congress of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2019)
  • 26 Jul 2019 Efficacy and adverse event data from a phase III OPTIMUM trial in Multiple sclerosis released by Janssen
  • 16 May 2019 Actelion Pharmaceuticals completes the phase III OPTIMUM trial in Multiple sclerosis in USA, Belarus, Bulgaria, Bosnia and Herzegovina, Canada, Czech Republic, Georgia, Greece, Italy, Lithuania, Mexico, Poland, Portugal, Romania, Russia, Serbia, Sweden, Turkey, United Kingdom, France, Israel, Ukraine, Germany, Latvia, Hungary, Finland, Croatia and Spain (EudraCT2012-000540-10) (NCT02425644)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top